A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Status: open

16-207 - [923977-5] Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

Treatment for Breast Cancer

Contact Us Or call (251) 445-9834

Description

The purpose of this study is to assess the effect of tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent central review.

Sponsors

This trial is sponsored by Cascadian Therapeutics.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.